Our Mission

To pioneer and deliver cutting-edge interventional devices designed for deep veins or the leg, enhancing patient outcomes by effectively treating and preventing a spectrum of severe venous diseases.

Our focus extends beyond the limitations of current technologies, encompassing chronic, and postthrombotic venous flow obstructions, occlusions, in-stent restenosis, and deep venous reflux – the prevalent late complications of Deep Vein Thrombosis.

Management Team

InterVene’s dynamic team possesses a wealth of experience from successful start-ups and leading medical device companies in the cardiovascular, neurovascular, peripheral, structural heart, aortic, and the venous interventional markets and is dedicated to expanding the boundaries of innovation to improve patient care.

group photo jan 25 24

They possess strong multi-position capabilities ranging from product development, manufacturing operations, and quality systems through clinical research, regulatory affairs, and marketing, including in new emerging fields.

Jeff Elkins
CEO

Abraham Van Scoit
Director, Manufacturing

Cathy Matthes
CFO

Mark Smutka
Consultant, Regulatory Affairs

Eric Dooley
VP, Quality Assurance

Board of Directors

InterVene is a product of the Stanford Biodesign Fellowship program and is a former Company-In-Residence at the Fogarty Institute for Innovation. 

Fletcher Wilson
Founder

Jeff Elkins
CEO

Jay Schmelter
Rivervest Ventures

Adam Berman
Alleviant Medical

Joe Biller
3x5 Partners

Ginger Glaser
Independent Director